SMARCA4 and cancer: First, by choosing an NGN PAM target closer to the edit of interest compared to a site with an NGG PAM, we introduced the substitution R350C (which mimics a human cancer mutation) in the C. elegans protein SWSN-4/SMARCA4 with an efficiency of 10% among dpy-10 co-edited animals (Fig. 4c and Supplementary Data 2).